Oramed in JV to Accelerate Development and Commercialization of Oral Insulin

 New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities

• Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq.
• OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology.
• HTIT to invest $60 million, Oramed to invest $15 million into OraTech.
• HTIT to provide a supply agreement for oral insulin capsules.
• New Phase 3 trial in the U.S. with a revised protocol expected to begin this quarter.
• OraTech to advance registration of oral insulin in the U.S. and other countries.
• OraTech to receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted, and commercialization preparations are underway by HTIT.

Further details on Oramed's plans and initiatives will be provided in a shareholder letter in the coming weeks.

https://www.prnewswire.com/news-releases/oramed-announces-transformative-joint-venture-to-accelerate-development-and-commercialization-of-oral-insulin-302373479.html